Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE pembrolizumab plus gemcitabine/cisplatin vs placebo plus gemcitabine/cisplatin in first-line advanced biliary tract cancer
jRCT2080224922Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more comparing Pembrolizumab plus gemcitabine/cisplatin with Placebo plus gemcitabine/cisplatin (2 arms). Primary endpoint: Overall survival. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on jRCT2080224922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224922.